Last updated: July 30, 2026
DEMADEX is bumetanide, a loop diuretic with a long regulatory and patent history in the US. From an IP and generic-readiness standpoint, DEMADEX does not present a near-term proprietary moat typical of newer branded injectables or specialty oral agents. Investment exposure is therefore driven primarily by: (1) current US label demand for loop diuresis, (2) competitive pricing and contracting, (3) form/strength share (tablets vs any liquid/other dosage, if marketed), and (4) any residual US patent or regulatory exclusivity that could delay generic entry for a specific presentation.
What is DEMADEX (bumetanide) and what is driving demand fundamentals?
DEMADEX is bumetanide, a loop diuretic used for fluid retention/edema. Core demand drivers are patient population stability and formulary placement in indications where loop diuretics remain standard of care.
Demand fundamentals that typically matter for a loop diuretic brand
- Chronic and recurring use patterns from edema etiologies.
- Payer formulary dynamics: loop diuretics are usually low-margin to branded, with heavy generic coverage.
- Channel contracting: wholesalers and PBMs set price pressure rapidly after generic proliferation.
- Substitution rate: bumetanide has class alternatives (e.g., furosemide, torsemide). Substitution depends on edema response history, clinician preference, and adverse event profile.
Investment implication
- If DEMADEX is not protected by meaningful US patents or exclusivity for a specific NDA/strength/presentation, then long-term fundamentals align to generic price compression cycles rather than sustained brand premium.
What patents protect DEMADEX (bumetanide) in the US and how many are still active?
If DEMADEX corresponds to an existing US branded NDA (or legacy brand) with Orange Book listings, protection is generally split into:
- Composition/formulation patents (active ingredient, polymorphs, salts, hydrates, prodrugs, excipients)
- Method-of-use patents (specific dosing regimens, specific patient subgroups, or edema indications)
- Process/manufacturing patents
- Device or packaging patents (less common for immediate-release oral solids)
- Regulatory exclusivities that can extend practical exclusivity beyond patent expiration (not usually long for an older diuretic)
Featured snippet answer
- For a loop diuretic with long market history, the practical expectation is that most, if not all, listed patents tied to the branded product have expired or are no longer enforceable, leading to broad generic availability.
Actionable investment lens
- The investable question is not “are there any patents,” but “are there any enforceable Orange Book listings tied to the specific NDA/strength that still constrain generic approvals.” Without that constraint, valuation reduces to near-term earnings power and contracting.
What is the Orange Book status of DEMADEX (bumetanide) and which listings matter for generic entry?
Orange Book status determines whether a generic applicant can seek ANDA approval without triggering patent litigation risk, based on:
- Patent expiration dates for each listed Orange Book patent
- Whether the FDA lists patents as “active” at the time of generic submission
- Patent assignment and any later changes in ownership
High-impact categories for investors
- Composition of matter patents that expire late and constrain “skinny” versus full design-around.
- Method-of-use patents that can trigger Paragraph IV for label carve-outs.
- Drug product/formulation patents that can require different dissolution/solid-state characteristics.
- Any exclusivity block (rare for older diuretics but can exist for certain NDA supplements or changes in formulation).
Featured snippet answer
- For older diuretics, Orange Book typically shows either no relevant active listings for the marketed presentation or listings that have effectively stopped blocking generics due to expiration.
When does DEMADEX (bumetanide) lose exclusivity and what is the generic launch timeline?
For older small molecules, the exclusivity timeline usually resolves into:
- Patent expiration (composition and formulation) across all listed patents
- Any remaining pediatric or other exclusivity periods, which can add a defined time extension
- Practical generic launch timing driven by:
- ANDA approval date
- 180-day exclusivity eligibility for first filers (if applicable)
- Settlement and consent decrees in any Paragraph IV case
Investment scenario
- If there is no active enforceable Orange Book listing, the “generic launch risk” is already realized. Equity risk shifts from future entry delay to ongoing price compression.
- If a narrow late-expiring listing exists for a specific strength/presentation, then entry could be delayed but usually not prevent long-run commoditization.
Which companies are challenging DEMADEX (bumetanide) and what Paragraph IV filings exist?
Paragraph IV challenges drive litigation and settlement dynamics, which can protect brand cash flows temporarily. For this scenario analysis, the critical input is:
- Whether there are any ANDA Paragraph IV filings against DEMADEX for the same NDA and strength
- Whether FDA litigation stays apply (30-month stay)
- Settlement terms that allocate market share or delay launch
Featured snippet answer
- For older loop diuretics, Paragraph IV activity is usually high in the past, and current brands often sit outside the active litigation pipeline.
What patent litigation affects DEMADEX (bumetanide) and how do settlements change launch dates?
Litigation affects:
- Whether generics launch at “patent cliff” or later
- Whether a settlement creates a multi-year market allocation
- Whether the brand receives a “pay-for-delay” economic benefit (settlement frameworks vary)
Investment sensitivity
- In a commodity-like profile, litigation that ended years ago matters less than current and next-cycle generic pricing.
- If any settlement is still binding for a specific market channel, the exposure is localized to that channel and strength.
What formulations are protected for DEMADEX (bumetanide) and can generics design around?
Design-around risk is low if patents are only on generic-friendly elements (e.g., different excipient levels) and high if patents cover:
- Solid-state forms
- Specific release characteristics
- Narrow formulation constraints required for bioequivalence
Investment implication
- For an immediate-release loop diuretic, generics can usually meet bioequivalence using standard process and formulation routes if there is no enforceable formulation patent.
- If a formulation patent exists and is still active, the generic must either:
- Certify non-infringement/invalidity (and potentially litigate), or
- Obtain a license (if infringement is likely)
How does DEMADEX (bumetanide) compare with other loop diuretics (furosemide, torsemide) for competitive pricing and substitution risk?
From an investment standpoint, competitive substitution is often more material than IP for older diuretics.
Typical substitution dynamics
- Prescribers often switch among loop diuretics based on response, tolerability, and historical response.
- Formularies frequently place multiple loop diuretics in tiers, with generics preferred.
Investment implication
- Even if DEMADEX retains patent protection, substitution to other loop diuretics can erode brand share unless payer/contracts lock in bumetanide.
What regulatory pathway issues (ANDA, 505(b)(2), labeling) affect DEMADEX generic entry?
For generics, the pathway is generally:
- ANDA referencing a listed brand NDA
- Bioequivalence demonstration to the RLD
- Label and patent certification per 21 CFR 314.94
Labeling and exclusivity
- Any labeling exclusivity (rare for long-standing diuretics) can affect the scope of generic carve-outs.
- If the branded label includes protected method-of-use content, generics may need carve-outs or litigation.
Investment implication
- Regulatory risk is usually manageable relative to IP, but label carve-outs can shift marketability and volume.
What generic entry risks exist for DEMADEX (bumetanide) and what is the “price cliff” scenario?
Price cliff mechanics
- Multiple ANDA launches typically accelerate price compression.
- PBM step therapy and formulary switching can amplify volume loss.
Investment scenario mapping
- No active blocking patents: market already commoditized; equity return depends on remaining brand contracts and inventory cycle timing.
- Narrow active patent for one strength/presentation: a limited “later entry” can preserve price for a specific subgroup, but long-run trend remains downward once the remaining listing expires.
Commercial landscape: where does DEMADEX generate revenue and what is the margin profile under generic pressure?
Revenue and margin are typically structured around:
- US sales concentration (likely, for a mature brand)
- Wholesale acquisition cost dynamics
- Rebates and contracting, which generally compress margins for legacy brands
Investment-relevant questions the market will price
- Whether DEMADEX can retain share versus equivalent diuretics
- Whether there are supply chain constraints that temporarily support price
- Whether payer conversion is slow in certain formularies
Investment implication
- In mature loop diuretics, financial performance often tracks utilization and pricing power more than “new product” growth.
How strong is the patent estate for DEMADEX (bumetanide) versus typical small-molecule brands?
For a mature small molecule, a “strong” estate typically implies:
- Late composition of matter for bumetanide, not merely formulation or process
- Or broad method-of-use protection tied to common prescribing patterns
Featured snippet answer
- For bumetanide/DEMADEX as a long-marketed diuretic, the patent estate is usually weak in blocking generic competition today.
Practical valuation implication
- Absent meaningful enforceable IP, the patent estate contributes little to risk-adjusted upside.
Geographic exposure: does DEMADEX face the same generic risks outside the US?
For small molecule legacy drugs, global generic penetration is often higher and earlier than in the US due to broader generic market formation.
Investment implication
- Even if the US is partially protected, ex-US price erosion can cap total brand profitability and reduce leverage for US pricing.
Manufacturing and IP barriers: can generics produce bumetanide at scale without infringement?
For mature APIs like bumetanide, the main barriers tend to be:
- Supply and process capability
- Regulatory and quality systems for ANDA approval
- Any enforceable process/manufacturing patents (less common today for legacy diuretics)
Investment implication
- When IP barriers are absent, scale competition becomes the dominant risk factor.
Investment scenarios and sensitivity: base case, downside, and upside
Base case (most likely for mature diuretics)
- Commodity pricing trend continues
- Any remaining brand premium is gradually competed away
- Earnings depend on volume stability and rebate/contract management
Downside
- Faster formulary conversion and multi-ANDA launch acceleration
- Margin compression via higher rebate pressure
- Loss of channel shelf support
Upside
- Temporary pricing stabilization from limited supply or delayed entry
- Residual enforceable patent blocking a specific strength/presentation longer than expected
- Higher-than-anticipated formulary retention in key plans
Key Takeaways
- DEMADEX (bumetanide) fits a mature small-molecule profile where investment upside is constrained by generic substitution and typically limited remaining IP protection.
- The primary investor drivers are US contracting dynamics, price compression pace, and any narrow residual Orange Book blocking listings tied to specific NDA presentations.
- Litigation and Paragraph IV effects matter only if they are active for the exact NDA/strength that generates material revenue; otherwise, the market is already in commoditized equilibrium.
- Competitive substitution across loop diuretics is a parallel demand risk that can overwhelm brand-specific pricing power.
FAQs
1) Is DEMADEX currently a high generic substitution risk compared with furosemide and torsemide?
Generic substitution risk is typically high because loop diuretics are interchangeable in many prescribing contexts and the class is widely generic.
2) Do method-of-use patents matter for bumetanide branding, or are composition patents the key issue?
Method-of-use can matter if the branded label includes protected regimens that generics must carve out; composition/formulation usually determine broader entry barriers, but for mature products these are often expired.
3) What market signals indicate a near-term DEMADEX price cliff?
New ANDA approvals or launch announcements tied to the same NDA/strength, plus formulary tier changes and stronger PBM contracting against the brand.
4) If DEMADEX has Orange Book listings, does that always stop generics from launching?
Not automatically. Generics can launch if patents are expired, invalidated, not infringed, or if they settle with label carve-outs that allow market entry.
5) How should investors think about settlement impacts for older diuretics like DEMADEX?
Settlements can delay a subset of launches or define market allocation, but for long-commoditized diuretics the main observable impact is on timing of price declines rather than on long-run brand survival.
References (APA)
- FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data
- FDA. 21 CFR Part 314 (Applications for FDA Approval to Market a New Drug). https://www.ecfr.gov/
